Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

5.57
-0.2900-4.95%
Post-market: 5.600.0300+0.54%19:30 EST
Volume:2.90M
Turnover:16.38M
Market Cap:1.23B
PE:-3.82
High:5.95
Open:5.76
Low:5.54
Close:5.86
52wk High:16.44
52wk Low:5.54
Shares:220.02M
Float Shares:183.00M
Volume Ratio:0.76
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4588
EPS(LYR):-1.4203
ROE:-93.48%
ROA:-42.19%
PB:2.78
PE(LYR):-3.92

Loading ...

Ocular Therapeutix Grants 200,000 Stock Options, 65,000 RSUs to New Executive Tiffany Howard

Reuters
·
Nov 20

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 20

Ocular Therapeutix Updates Diabetic Retinopathy Study, but Investors Still Await Results

TIPRANKS
·
Nov 20

Ocular Therapeutix Price Target Maintained with a $28.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 17

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Simply Wall St.
·
Nov 15

Ocular Therapeutix (OCUL) Stock Looks Priced For Perfection Despite Its 202% Run

Simply Wall St.
·
Nov 13

Pelthos Q3 Zelsuvmi Revenue Jumps 114%, Net Loss Narrows

Reuters
·
Nov 12

EyePoint Pharmaceuticals Q3 Revenue Falls, Net Loss Widens

Reuters
·
Nov 12

Belite Bio Q3 Loss Widens on Higher Costs

Reuters
·
Nov 12

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.
·
Nov 12

QT Imaging Q3 Revenue Jumps 75% on Scanner Sales

Reuters
·
Nov 11

Ocular Therapeutix Grants Director Riad Sherif 28,000 Restricted Stock Units

Reuters
·
Nov 11

Kalaris Therapeutics Q3 Net Loss Narrows as Expenses Fall

Reuters
·
Nov 10

Needham Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

TIPRANKS
·
Nov 10

RBC Capital Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
Nov 10

Governance Red Flags at Ocular Therapeutix: CMO-Centric Incentives and Change-in-Control Payouts Heighten Shareholder and Transaction Risk

TIPRANKS
·
Nov 10

Harrow Q3 Revenue Slightly Beats Estimates on Branded Product Growth; Cuts Ebitda Outlook

Reuters
·
Nov 10

Ocular Therapeutix, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Nov 09

Earnings Flash (OCUL) Ocular Therapeutix Posts Q3 Net Loss $0.42 a Share, vs. FactSet Est of $0.36 Loss

MT Newswires Live
·
Nov 09

Ocular Therapeutix Q3 Loss Widens as Product Revenue Drops, Costs Rise

Reuters
·
Nov 09